Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Inovio Pharmaceuticals, Inc. (NASDAQ: INO).

Full DD Report for INO

You must become a subscriber to view this report.


Recent News from (NASDAQ: INO)

Inovio Announces Initiation of "MD Anderson's HPV-Related Cancers Moon Shot" Phase 2 Trial in New HPV Indications
Phase 2 cancer study will evaluate T cell-activating immunotherapy MEDI0457  with MedImmune’s durvalumab targeting several HPV-related cancers PLYMOUTH MEETING, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the dosing of th...
Source: GlobeNewswire
Date: December, 04 2018 08:00
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment conferences: Stifel 2018 Healthcare Conference Presentation Dr. J. Joseph Kim, President & CEO ...
Source: GlobeNewswire
Date: November, 05 2018 08:00
Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses
PLYMOUTH MEETING, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX ® -GP delivered via intradermal route demonstrated durable and robust antibody and T cell immune responses measured throughout the d...
Source: GlobeNewswire
Date: October, 25 2018 08:00
Inovio Doses 1st Subject in Phase 1/2 Clinical Trial For Vaccine Against Deadly MERS Infection
PLYMOUTH MEETING, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today announced the dosing of the first subject with its vaccine to prevent infection from the deadly MERS virus (Middle East Respiratory Syndrome) in a Phase 1/2a study to evaluat...
Source: GlobeNewswire
Date: September, 05 2018 08:00
Inovio up 2% on start of early-stage study of hep C vaccine
Inovio Pharmaceuticals ( INO +1.5% ) is up on below-average volume in response to its announcement that dosing is underway in a Phase 1 clinical trial evaluating a vaccine for the prevention of hepatitis C virus (HCV) infection. More news on: Inovio Pharmaceuticals, Inc., Healthcare st...
Source: SeekingAlpha
Date: September, 04 2018 13:20
Inovio and Korean Partner Dose 1st Subject In Trial to Develop World's First Vaccine to Prevent Hepatitis C Infection
PLYMOUTH MEETING, Pa., and SEOUL, Korea, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science (KSE: 011000) today announced they have dosed the first patient in a Phase 1 study designed to evaluate a preventive vaccine against hepatitis C inf...
Source: GlobeNewswire
Date: September, 04 2018 01:00
Today's Research Reports on Trending Tickers: Celldex Therapeutics and Inovio Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike in September. The Dow Jones Industrial Average dropped 0.34 percent to close at 25...
Source: ACCESSWIRE IA
Date: August, 23 2018 08:00
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment conferences: Rodman and Renshaw 20 th Annual Global Investment Conference, sponsored by H...
Source: GlobeNewswire
Date: August, 21 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-145.405.265.495.23766,777
2018-02-264.264.284.31014.21426,211
2018-02-234.184.244.284.11806,309
2018-02-224.264.184.284.14860,704
2018-02-214.224.224.304.17680,391

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0748,399128,36437.7045Short
2018-12-0698,540167,35758.8801Short
2018-12-0455,760102,33954.4856Short
2018-12-0362,683140,80144.5189Short
2018-11-3073,369192,37538.1385Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INO.


About Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

Logo for Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

The achievements of stimulating the immune system through vaccination have been profound. INO s synthetic vaccines are designed to treat as well as prevent illnesses, aiming to break the body s tolerance of cancerous cells and protect against diverse while changing strains of infectious diseases. INO s SynCon vaccines are designed to provide universal cross strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio s proprietary electroporation delivery, have been shown in humans to generate best in class immune responses with a favorable safety profile.

 

Contact Information

 

 

Current Management

  • Terry E. Gibson / COO
  • Peter Kies / CFO
  • E. Terrie RoeDierlam / Secretary

Current Share Structure

  • Market Cap: $455,635,419 - 05/17/2018
  • Issue and Outstanding: 90,403,853 - 03/08/2018

 


Recent Filings from (NASDAQ: INO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 07 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: June, 11 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: June, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 25 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 28 2018

 

 


Daily Technical Chart for (NASDAQ: INO)

Daily Technical Chart for (NASDAQ: INO)


Stay tuned for daily updates and more on (NASDAQ: INO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: INO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of INO and does not buy, sell, or trade any shares of INO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/